Navigation Links
Cephalon Submits Supplemental New Drug Application for FENTORA
Date:11/12/2007

of improper patient selection and/or improper dosing. FENTORA is contraindicated in the management of acute or postoperative pain including headache/migraine. Life-threatening respiratory depression could occur at any dose in patients not regularly taking around-the-clock opioids. The label for FENTORA is currently being updated to reflect these and other important safety considerations. PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE

IMPORTANT WARNINGS IN THIS LABEL.

FENTORA contains fentanyl, an opioid agonist and a Schedule II controlled substance, with an abuse liability similar to other opioid analgesics. FENTORA can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing FENTORA in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse or diversion. Schedule II opioid substances which include morphine, oxycodone, hydromorphone, oxymorphone, and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression.

FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least 60 mg of oral morphine/day, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. Because life-threatening respiratory depression could occur at any dose in opioid non-tolerant patients, FENTORA is contraindicated in the management of acute or postoperative pain. This product is not indicated for use in opioid nontolerant patients.

Patients and their caregivers must be instructed that FENTORA contains a medicine in an amount which can b
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
9. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
10. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
11. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... 2014 PharmaBoardroom,s new report, ... and available for free download , digs deep into ... growth in the sector today. One area where ... been in developing a homegrown pharmaceutical manufacturing base, even if ... remains some way off. A cursory comparison with neighboring ...
(Date:12/24/2014)... Dec. 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... filed a Clinical Trial Application (CTA) with the ... Agency (MHRA) seeking regulatory approval to initiate clinical trials ... Citrate. Contingent on the Company receiving CTA ... I trial to assess the safety, tolerability and dose ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , ... a vital role in Merrimack,s acquisition of Hermes Biosciences and partnership with sanofi-aventis ... Cambridge, MA (PRWEB) ... the discovery and development of novel treatments for cancer and inflammation, today announced that ...
... ... Look , ... 5, 2010 -- HealthTalker , the leader in word of mouth (WOM) marketing campaigns ... Massachusetts headquarters. HealthTalker also reported strong revenue and significant year-over-year growth for its third ...
... on a single atom oflet,s saygold to detach it from ... measure of the astonishing progress in nanotechnology that questions that ... being asked by engineers. To help with the answers, a ... (NIST) has built an ultra-stable instrument for tugging on chains ...
Cached Biology Technology:Merrimack Pharmaceuticals Promotes William Sullivan to Vice President of Finance 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 2HealthTalker Programs Leveraging the Power of Word of Mouth Find Huge Success for Pharmaceutical Industry 3NIST researchers holding steady in an atomic-scale tug-of-war 2
(Date:12/17/2014)...  Automation is fundamentally transforming the travel experience ... international borders. Over the past decade, ePassports, biometric ... travelers to self process through border control via ... an increasing number of airports, seaports, and land ... to Maxine Most , Principal at Acuity ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) ... Market in the APAC Region 2015-2019"  report to ... emerging in this market is advances in technology. ... to upgrade biometric solutions to the latest standard ...
(Date:12/11/2014)...  That blood pressure plays a role in human health ... medical term for high blood pressure – was first described ... cuff that,s used in measuring blood pressure was invented in ... about hypertension, its triggers and its effects. In fact, recent ... the best ways to treat it. For example, ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... - (Toronto) A new study from the Centre for ... a variation of a specific gene may play a role ... of Alzheimer,s cases. This innovative study has combined genetics and ... developing late-onset Alzheimer,s disease long before symptoms appear. The ...
... examine the response to noise of a diverse range of ... found that many families of crustaceans previously assumed to be ... Lizard Island on the Great Barrier Reef, the team collected ... webs. On each of 34 nights, one light trap ...
... (Minority Access to Research Careers) Program has announced the ... Sports Medicine (ACSM) Southeast Chapter Annual Meeting in Greenville, ... to promote the entry of underrepresented minority students, postdoctorates ... community and to encourage the participation of young scientists ...
Cached Biology News:Combining brain imaging, genetic analysis may help identify people at early risk of Alzheimer's 2Rowdy residents warn crustaceans away from perilous reefs 2
Recombinant Human HGF...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
... histochemically detect specific senescence ... in cultured cells and ... marker is only present ... found in presenescent/quiescent/immortal cells. ...
Recombinant Mouse LIGHT/TNFSF14...
Biology Products: